생물학적 반응조절물질 = Biologic response modifiers

다국어 초록 (Multilingual Abstract)

Biotherapy, often called biological therapy or immunotherapy, aims at supporting and helping in the treatment of human disease without chemical drugs and invasive therapies, by restoring the natural immune system. It is also used to reduce certain side effects that may be caused by some treatments against cancer, autoimmune diseases, or other diseases. Biotherapy employs substances called biological response modifiers (BRMs). The term BRM is often used synonymously with the terms immunomodulator and immunostimulant. BRMs are agents that modify the host’s response to pathogens with resultant beneficial prophylactic or therapeutic effects. The use of BRMs had rapidly expanded since the introduction of the first diagnostic antibodies. They are now employed in oncology, autoimmune diseases, inflammatory diseases,and transplantation medicine. BRMs used in biological therapy include interferones, interleukins,colony-stimulating factors, monoclonal antibodies, differentiation agents, tyrosine kinase inhibitor,tumor necrosis factor, vaccines, and nonspecific immunomodulating agents. BRMs are widely accepted in the treatment of certain types of cancer and rheumatoid arthritis, while others are being tested in research studies. This article reviewed the clinical use and side effects of BRMs in cancer and other diseases.

참고문헌 (Reference)

1 홍명주, "류마티스 질환의 생물학적 치료제" 대한내과학회 82 (82): 549-561, 2012

2 Rini BI, "Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions" 13 : 1098-1106, 2007

3 Kaushansky K, "Thrombopoietin" 355 : 2071-2084, 2006

4 Weaver AL, "The impact of new biologicals in the treatment of rheumatoid arthritis" 43 (43): 17-23, 2004

5 Oettgen HF, "The history of cancer immunotherapy, In Biologic ther-apy of cancer" Lippincott 81-101, 1991

6 Grunhagen DJ, "Technology insight: utility of TNF-alpha-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities" 3 : 94-103, 2006

7 Antoni CE, "Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)" 52 : 1227-1236, 2005

8 Kuroki M, "Signi-ficance of tumor-associated antigens in the diagnosis and ther-apy of cancer: an overview" 22 : 4255-4264, 2002

9 Drueke TB, "Normalization of hemoglobin level in patients with chronic kidney disease and anemia" 355 : 2071-2084, 2006

10 Antoni C, "Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial" 64 : 1150-1157, 2005

11 Tompkins WA, "Immunomodulation and therapeutic effects of the oral use of interferon-alpha: mechanism of action" 19 : 817-828, 1999

12 Hank JA, "Immunogenicity of the hu14.18-IL2 immunocytokine mole-cule in adults with melanoma and children with neuroblas-toma" 15 : 5923-5930, 2009

13 Rubinstein I., "Human VIP-alpha: an emerging biologic response modifier to treat primary pulmonary hypertension" 3 : 565-569, 2005

14 Mihich E., "Historical overview of biologic response modifiers" 18 : 456-466, 2000

15 Mease PJ, "Etanercept treat-ment of psoriatic arthritis: safety, efficacy, and effect on dis-ease progression" 50 : 2264-2272, 2004

16 Mease PJ, "Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial" 356 : 385-390, 2000

17 Serebruany VL, "Eltrombopag (Promacta), a thrombopoietin receptor agonist for the treat-ment of thrombocytopenia: current and future considerations" 17 : 68-74, 2010

18 Ghany MG, "Diagnosis, management, and treatment of hepatitis C: an update" 49 : 1335-1374, 2009

19 Osterman MT, "Current and future anti-TNF therapy for inflammatory bowel disease" 10 : 195-207, 2007

20 Kuroki M, "Biological response modifiers used in cancer biotherapy" 32 : 2229-2233, 2012

21 Murthy TE, "Biological response modifiers" 2 : 2152-2160, 2010

22 Bisht M, "Biological response modi-fiers: current use and future prospects in cancer therapy" 47 : 443-451, 2010

23 Huynh N, "Biologic response modifier therapy for psoriatic ocular inflammatory disease" 16 : 89-93, 2008

24 Park SH, "Biologic agent for rheumatoid arthritis" 32 : 68-76, 2012

25 Krauss J, "Application of recom-binant antibodies in cancer patients, In Recombinant antibodies for cancer therapy: methods and protocols" Humana Press 27-53, 2003

26 Mease PJ, "Adalimumab for the treatment of patients with mode-rately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial" 52 : 3279-3289, 2005